HanAll Biopharma said it would receive a $10 million milestone payment from Roivant Sciences, a Switzerland-based company, for the technology transfer regarding an investigational autoimmune disease treatment HL161 (ingredient: batoclimab).In a regulatory filing on Thursday, HanAll Biopharma said it
Huons will produce isoproterenol-based medicines, the supply of which has been suspended by Pfizer Korea.Huons has been selected to receive support from the Ministry of Food and Drug Safety in return for supplying essential national medicines stably and taking over the production of isoproterenol in
Jeil Pharmaceutical said on Thursday that the company will provide an exclusive domestic supply of osteoporosis treatment Bonviva (ingredients: ibandronate sodium) and Bonviva Plus (ibandronate sodium, cholecalciferol), in Korea.Jeil signed the exclusive sales deal with Pharmanovia, a U.K. pharmaceu
GenNBio said it obtained approval from the Ministry of Food and Drug Safety (MFDS) for a phase 1 clinical trial to test transplanting sterile pig pancreatic islets into diabetic patients.According to the company, xenogenic pancreatic islet transplantation is a low-burden treatment that can be perfor
Genome & Company said on Tuesday that it will drop the phase-1b clinical trials of GEN-001 in solid cancer in the U.S. and Korea, citing too much competition in new drug development for solid cancer. Instead, the company will focus on its gastric and biliary tract indications in phase-2 combination
Yuhan Corp. said it will seek approval from the U.S. Food and Drug Administration (FDA) for its lung cancer treatment, Leclaza, as first-line therapy for non-small cell lung cancer (NSCLC) in earnest from next year.Leclaza (YH25448) is an oral, highly potent, mutant-selective, and irreversible EGFR
SK Bioscience said on Tuesday that it has published the first Task Force on Climate-related Financial Disclosures (TCFD) report containing business sustainability and response strategies to fight climate change, following its ESG report in June.TCFD is an international consultative body established
Roche’s ALK (anaplastic lymphoma kinase)-positive target anticancer therapy, Alecensa (alectinib), has shown consistent results with the existing studies in its long-term clinical trial of Asian, including Korean, patients, reaffirming its safety and effectiveness.In the ESMO (European Society for M
CHA Vaccine Institute received approval from the Ministry of Food and Drug Safety (MFDS) on Monday for a phase 1 clinical trial plan to develop CVI-VZV-001, a candidate for a recombinant protein shingles vaccine with the potential to suppress postherpetic neuralgia (PHN) effects.Accordingly, the ins
The HIV Care Continuum & Beyond (HIVCCB) recommended 14 methods to end HIV in Asia by 2030 in a white paper at a forum in Bangkok, Thailand, Saturday.The HIVCCB was established and funded by ViiV Healthcare, a company specializing in HIV, to develop a white paper that provides actionable insights in
Handok said it obtained regulatory nod for Vyxeos (ingredients: daunorubicin, cytarabine), from the Ministry of Food and Drug Safety (MFDS) on Wednesday.Vyxeos can be used for “treatments of patients with acute myeloid leukemia(t-AML) or acute myeloid leukemia with myelodysplasia related changes (AM
The Korea Disease Control and Prevention Agency (KDCA) said on Friday that, thanks to public-private partnership efforts, the winter vaccination rate has continued to rise since November.Korea's daily Covid-19 cases fell below 60,000 for the second straight day on Friday, reporting 52,987 new Covid-
Yuhan Corp’s Leclaza (ingredient: lazertinib) demonstrated a 20.6 months of median progression-free survival (mPFS) as the first-line therapy for non-small cell lung cancer (NSCLC) treatment in a global phase 3 trial, the company said.Specifically, Leclaza’s mPFS in EGFR-mutated NSCLC patients was m
Roche has withdrawn Tecentriq’s indication for bladder cancer in the United States, but experts predict its effects on patients in clinical practice will not be significant.On Nov. 28, Genentech, an affiliate of Roche, said it would voluntarily withdraw Tecentriq’s U.S. indication for treating adult
Healthcare experts and industry leaders emphasized the importance of ESG (Environmental, social, governance) management in the pharmaceutical and biotech industry at a forum hosted by Korea Biomedical Review (KBR) in Seoul on Wednesday.KBR, a sister paper of Korean Doctors’ Weekly, launched the K-He
Takeda Pharmaceuticals Korea said Kynteles Prefilled Pen Inj. (Kynteles SC), an inflammatory bowel disease(IBD) treatment, started to be covered by health insurance on Thursday.Kynteles SC is subcutaneously injectable at home with the same efficacy as Kynteles intravenous injection (IV).Kynteles SC
Daewoong Pharmaceutical said on Thursday Envlo (ingredient: enavogliflozin), a new diabetes drug that inhibits sodium-glucose cotransporter 2 (SGLT-2), obtained domestic approval as monotherapy, metformin combination therapy, and metformin and gemigliptin combination therapy, to treat type-2 diabete
Celltrion said Wednesday that the company has secured a more stable basis of sales by winning patent rights for RemsimaSC, its autoimmune disease treatment, in an increasing number of countries.Celltrion has applied for patents for the formulation and the administration method of RemsimaSC in the U.
Lunsumio, Roche Korea’s lymphoma treatment, has become the first drug designated as the subject of the government’s Global Innovative products on Fast Track (GIFT).The Ministry of Food and Drug Safety said Tuesday that it had picked Lunsumio Inj. as the first product of the government’s GIGT system
No fewer than 92 percent of Korean doctors think pharmaceutical companies’ digital marketing activities enhanced in the non-contract era help them prescribe drugs, according to a survey.The largest number of respondents selected Daewoong Pharmaceutical as the drugmaker that conducts digital marketin